Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors.
Drug Eruptions
/ etiology
History, 21st Century
Humans
Immune Checkpoint Inhibitors
/ adverse effects
Immunotherapy
/ adverse effects
International Agencies
/ organization & administration
Neoplasms
/ immunology
Palliative Care
/ methods
Palliative Medicine
/ organization & administration
Severity of Illness Index
Societies, Medical
/ organization & administration
Bullous dermatoses
Corticosteroids
Cutaneous IrAEs
Inflammatory dermatitis
Pruritus
Skin rash
Vitiligo
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
24
04
2020
accepted:
20
08
2020
pubmed:
29
8
2020
medline:
21
1
2021
entrez:
29
8
2020
Statut:
ppublish
Résumé
Immune checkpoint inhibitors (ICIs) frequently result in cutaneous immune-related adverse events (IrAEs). Although the majority of these events are mild-to-moderate in severity, up to 5% are severe, which may lead to morbidity and dose interruption or discontinuation of ICI therapy. In addition, up to 25% of dermatologic IrAEs are corticosteroid-refractory or corticosteroid-dependent. These 2020 MASCC recommendations cover the diagnosis and management of cutaneous IrAEs with a focus on moderate-to-severe and corticosteroid-resistant events. Although the usage of immune-suppressive therapy has been advocated in this setting, there is a lack of randomized clinical trial data to provide a compelling level of evidence of its therapeutic benefit.
Identifiants
pubmed: 32856211
doi: 10.1007/s00520-020-05706-4
pii: 10.1007/s00520-020-05706-4
pmc: PMC8996262
mid: NIHMS1743129
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Historical Article
Journal Article
Practice Guideline
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
6119-6128Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NIAMS NIH HHS
ID : U01 AR077511
Pays : United States
Références
Eur J Cancer. 2019 Mar;110:107-109
pubmed: 30785013
Lung Cancer. 2017 Jul;109:58-61
pubmed: 28577951
Eur J Cancer. 2017 Aug;81:237-239
pubmed: 28438440
Int J Dermatol. 2018 Jun;57(6):664-669
pubmed: 29630716
SAGE Open Med Case Rep. 2020 Jan 13;8:2050313X19897707
pubmed: 31976071
Cureus. 2019 Oct 2;11(10):e5824
pubmed: 31754559
Front Pharmacol. 2017 Feb 08;8:49
pubmed: 28228726
J Immunother Cancer. 2017 Nov 21;5(1):95
pubmed: 29162153
Clin Exp Dermatol. 2017 Apr;42(3):309-312
pubmed: 28211077
JAMA Dermatol. 2017 Jun 1;153(6):603-605
pubmed: 28355425
J Cutan Pathol. 2017 Apr;44(4):381-384
pubmed: 28000240
Eur J Cancer. 2016 Jun;60:12-25
pubmed: 27043866
Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):834-851
pubmed: 28918995
JAMA Dermatol. 2015 Nov;151(11):1206-1212
pubmed: 26222619
Cancer Immunol Res. 2016 May;4(5):383-9
pubmed: 26928461
Nat Rev Clin Oncol. 2016 Aug;13(8):473-86
pubmed: 27141885
Clin Cancer Res. 2016 Aug 15;22(16):4023-9
pubmed: 26957557
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
Curr Probl Cancer. 2017 Mar - Apr;41(2):125-128
pubmed: 28190531
J Cutan Pathol. 2017 Feb;44(2):158-176
pubmed: 27859479
Cancer Treat Rev. 2017 Jun;57:36-49
pubmed: 28550712
JAMA Dermatol. 2016 Oct 1;152(10):1128-1136
pubmed: 27411054
JAAD Case Rep. 2016 Dec 03;2(6):442-444
pubmed: 27981213
Nat Rev Clin Oncol. 2020 Aug;17(8):504-515
pubmed: 32246128
Lancet. 2017 Apr 22;389(10079):1630-1638
pubmed: 28279484
Cancer Immunol Res. 2015 Jan;3(1):18-22
pubmed: 25287118
Am J Clin Dermatol. 2018 Jun;19(3):345-361
pubmed: 29256113
Oncologist. 2018 Oct;23(10):1119-1126
pubmed: 30018132
J Am Acad Dermatol. 2019 Apr;80(4):990-997
pubmed: 30399387
Am J Dermatopathol. 2017 Jan;39(1):23-27
pubmed: 28045749
JAAD Case Rep. 2018 Feb 23;4(3):229-231
pubmed: 29687056
Eur J Cancer. 2016 Jun;60:190-209
pubmed: 27085692
Clin Cancer Res. 2016 Feb 15;22(4):886-94
pubmed: 26446948
Ann Oncol. 2015 Dec;26(12):2375-91
pubmed: 26371282
Eur J Dermatol. 2017 Apr 1;27(2):205-208
pubmed: 28251900
JAAD Case Rep. 2019 Oct 03;5(10):898-903
pubmed: 31646161
J Cutan Pathol. 2016 Apr;43(4):339-46
pubmed: 26762844
Curr Opin Oncol. 2016 Jul;28(4):254-63
pubmed: 27136138
Cancer Immunol Res. 2019 Jun;7(6):860-865
pubmed: 30996018
J Immunother. 2016 Jun;39(5):202-4
pubmed: 27163740
J Eur Acad Dermatol Venereol. 2017 May;31(5):e254-e257
pubmed: 27739129
J Am Acad Dermatol. 2016 Mar;74(3):455-61.e1
pubmed: 26793994
J Eur Acad Dermatol Venereol. 2017 Aug;31(8):e349-e350
pubmed: 28129461
Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142
pubmed: 28881921